ArticleOncology reports2023
Microcystin‑leucine arginine promotes colorectal cancer cell proliferation by activating the PI3K/Akt/Wnt/β‑catenin pathway.
Article in Oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Metabolic reprogramming in colorectal cancer: Mechanisms and therapeutic insights.Genes & diseases · 2027Review
- Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.Non-coding RNA research · 2025Review
- Gene prediction of immune cells association between gut microbiota and colorectal cancer: a Mendelian randomization study.Frontiers in immunology · 2025Article
- Microcystin-LR activates serine/threonine kinases and alters the phosphoproteome in human HepaRG cells.Toxicon : official journal of the International Society on Toxinology · 2024Article
- Article
- Article
- Article
- MicroRNA-203a inhibits breast cancer progression through the PI3K/Akt and Wnt pathways.Scientific reports · 2024Article
- Association between branched-chain amino acid levels and gastric cancer risk: large-scale prospective cohort study.Frontiers in nutrition · 2024Article
- Cell division cycle 42 effector protein 4 inhibits prostate cancer progression by suppressing ERK signaling pathway.Biomolecules & biomedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microcystin‑leucine arginine (MC‑LR) is an environmental toxin produced by cyanobacteria and is considered to be a potent carcinogen. However, to the best of our knowledge, the effect of MC‑LR on colorectal cancer (CRC) cell proliferation has never been studied. The aim of the present study was to investigate the effect of MC‑LR on CRC cell proliferation and the underlying mechanisms. Firstly, a Cell Counting Kit‑8 (CCK‑8) assay was conducted to determine cell viability at different concentrations, and 50 nM MC‑LR was chosen for further study. Subsequently, a longer CCK‑8 assay and a cell colony formation assay showed that MC‑LR promoted SW620 and HT29 cell proliferation. Furthermore, western blotting analysis showed that MC‑LR significantly upregulated protein expression of PI3K, p‑Akt (Ser473), p‑GSK3β (Ser9), β‑catenin, c‑myc and cyclin D1, suggesting that MC‑LR activated the PI3K/Akt and Wnt/β‑catenin pathways in SW620 and HT29 cells. Finally, the pathway inhibitors LY294002 and ICG001 were used to validate the role of the PI3K/Akt and Wnt/β‑catenin pathways in MC‑LR‑accelerated cell proliferation. The results revealed that MC‑LR activated Wnt/β‑catenin through the PI3K/Akt pathway to promote cell proliferation. Taken together, these data showed that MC‑LR promoted CRC cell proliferation by activating the PI3K/Akt/Wnt/β‑catenin pathway. The present study provided a novel insight into the toxicological mechanism of MC‑LR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.